Treatment of osteoporosis with bone-forming drugs and others. Mechanism of action of PTH 1-34, intact PTH, denosumab, strontium ranelate, calcitonin and new drugs in perspective;Tratamiento de la osteoporosis con fármacos osteoformadores y otros. Mecanismo de acción de la PTH 1-34, PTH intacta, denosumab, ranelato de estroncio, calcitonina y nuevos fármacos en perspectiva

Medicine

Volumn 10, Issue 60, 2010, Pages 4144-4148

  Nogues Solan X ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956020087     PISSN: 03045412     EISSN: 15788822     Source Type: Journal    
DOI: 10.1016/S0304-5412(10)70174-8     Document Type: Article

References (17)

1. J. González-Macías, N. Guañabens, C. Gómez-Alonso, L. del Río, M. Muñoz, and M. Delgado Hawkins Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral Rev Clin Esp 208 Supl 1 2008 1 24
2. Osteoporosis - primary prevention: guidance National Ins-titute for Health and Clinical Excellence Disponible en: www.nice.org.uk/TA160.
3. R.L. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH Bone 40 2007 1434 1446
4. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.Y. Reginster Effect of Parathyroid Hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
5. K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, and K.A. Taylor Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2007 2028 2039
6. E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, and A. Díez-Pérez The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 2003 9 17
7. R. Eastell, T. Nickelsen, F. Marin, C. Barker, P. Hadji, and J. Farrerons Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS) J Bone Miner Res 24 2009 726 736
8. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, J.R. Zanchetta The Treatment of Osteoporosis with Parathyroid Hormone Study Group Effect of Recombinant Human Parathyroid Hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial Ann Intern Med 146 2007 326 339
9. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, and E. Timms Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci U S A 96 1999 3540 3545
10. S. Khosla Minireview: the OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
11. S.R. Cummings, J. San Martín, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
12. P.J. Meunier, C. Roux, E. Seeman, S. Ortolani, J.E. Badurski, and T.D. Spector The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468
13. C.H. Chesnut 3rd, S. Silverman, K. Andriano, H. Genant, A. Gimona, and S. Harris A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 109 2000 267 276
14. H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, and N. Verbruggen Odanacatib, a cathepsin-K Inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density J Bone Miner Res 25 2010 937 947
15. www.bonekey-ibms.org
16. www.seiomm.org
17. www.stanford.edu/~rnusse/wntwindow.html